Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces risk of disease progression and hospitalization in high-risk subjects but no clear data on end-stage renal disease are available. We report 2 cases of Bamlanivimab/Etesevimab administration to two not hospitalized chronic hemodialysis patients with SARS-CoV2 infection. Since they are large molecules (human immunoglobulin G1) with molecular weight of 146,000 Da, administration was conducted during the second hour of the dialysis session with no adverse reaction. Conclusions: Intradialytic administration of Bamlanivimab/Etesevimab could be considered safe and may allow adequate clinical observation time without hospital-stay prolongation.

Keywords:
Bamlanivimab, Etesevimab, SARS-CoV-2, Hemodialysis, COVID-19
1.
Hsu
 
CM
,
Weiner
 
DE
.
COVID-19 in dialysis patients: outlasting and outsmarting a pandemic
.
Kidney Int
.
2020
;
98
:
1402
–
4
.
https://doi.org/10.1016/j.kint.2020.10.005
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Xiong
 
F
,
Tang
 
H
,
Liu
 
L
,
Tu
 
C
,
Tian
 
J
,
Lei
 
C
,  
Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China
.
J Am Soc Nephrol
.
2020
;
31
(
7
):
1387
–
97
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Hiranoand
 
T
,
Murakami
 
M
.
COVID-19: a new virus, but a familiar receptor and cytokine release syndrome
.
Immunity
.
2020 May
;
52
(
5
):
731
–
3
.
https://doi.org/10.1016/j.immuni.2020.04.003
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Gottlieb
 
RL
,
Nirula
 
A
,
Chen
 
P
,
Boscia
 
J
,
Heller
 
B
,
Morris
 
J
,  
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
.
JAMA
.
2021
;
325
(
7
):
632
–
44
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Chen
 
P
,
Nirula
 
A
,
Heller
 
B
,
Gottlieb
 
RL
,
Boscia
 
J
,
Morris
 
J
,  
SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid
.
N Engl J Med
.
2021
;
384
:
229
–
37
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.